Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
15-LO2 CRISPR/Cas9 KO Plasmid (m): sc-419090
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- 15-LO2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the 15-LO2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: 15-LO2 Antibody (F-10): sc-376795
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
15-LO2 CRISPR/Cas9 KO Plasmid (m) | sc-419090 | 20 µg | $397.00 |
Overview
Alox8 encodes arachidonate 15-lipoxygenase 2 (15-LO2), a non-heme iron dioxygenase that oxygenates polyunsaturated fatty acids to generate bioactive lipid mediators. In mouse tissues, 15-LO2-derived oxylipins can modulate redox balance, membrane lipid remodeling, and inflammatory signaling through eicosanoid and lipid-peroxidation networks. Alox8 activity intersects with innate immune pathways and epithelial barrier biology by shaping local mediator profiles that influence cytokine production and leukocyte recruitment. Dysregulated lipoxygenase-dependent lipid signaling has been linked to inflammatory phenotypes and metabolic stress responses, making Alox8 a useful node for studying disease-relevant lipid mediator circuitry.
15-LO2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Alox8 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Alox8 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Alox8 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish 15-LO2 protein expression.
This CRISPR knockout system enables efficient generation of Alox8-deficient cell models for investigation of 15-LO2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Alox8 exon(s) critical for 15-LO2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Alox8 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by 15-LO2 CRISPR/Cas9 KO Plasmid (m) and 15-LO2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Alox8 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by 15-LO2 HDR Plasmid (m) and 15-LO2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Alox8 homology arms to support homology-directed repair at defined Alox8 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.